Romiplostim (Nplate)

Romiplostim (Nplate) is covered for FDA‑approved immune thrombocytopenia (ITP) and HS‑ARS and for specified compendial uses (thrombocytopenia from low‑to‑intermediate‑risk MDS and chemotherapy‑induced thrombocytopenia), and is not covered for indications outside these listed uses. Coverage requires hematologist/oncologist prescribing or consultation, specific platelet thresholds (ITP/MDS <30×10^9/L or <50×10^9/L with increased bleeding risk; chemotherapy <100×10^9/L with ≥3 weeks since chemo or chemo delay), prior therapies or splenectomy for ITP, age ≥18 for chemo indication, adherence to dosing/frequency caps, defined approval durations (initial generally 3 months; HS‑ARS one dose), and reauthorization only with documented clinical benefit.

"Treatment of thrombocytopenia in individuals with immune thrombocytopenia who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy."